EXPANDCOLLAPSE

• +Healthcare Professionals
  • +Diabetes care
    • Pharmaceuticals
      • Victoza®
      • Levemir®
      • NovoMix® 30
      • NovoRapid®
      • Insulatard®
      • Mixtard®
      • Actrapid®
      • NovoNorm®
      • R&D Pipeline
    • Injection devices
      • FlexPen®
      • NovoPen® 4
      • NovoPen® 3
      • NovoPen® Junior
      • InnoLet®
      • NovoLet®
      • Innovo®
        • Manual
      • InDuo®
        • Manual
    • Needles
      • NovoFine®
      • NovoFine® Autocover®
      • NovoTwistTM
    • HypoKit
      • GlucaGen® HypoKit
  • +Growth hormone therapy
    • Pharmaceutical information
      • Norditropin®
    • Injection devices
      • Norditropin NordiFlex®
      • NordiFlex PenMate®
      • NordiPen® with Norditropin® SimpleXx®
      • NordiPenMate®
      • Norditropin® NordiLet®
    • Needles
      • NovoFine®
    • Indications
      • GHD (Growth hormone deficiency)
      • GHDA (Growth hormone deficiency in adults)
      • SGA (Small for gestational age)
      • Turner syndrome
      • Noonan syndrome
      • Skeletal dysplasia
      • Chronic renal insufficiency
    • Programmes & support
      • NordiNet® (outcomes registry)
      • NordiScience® (HCP support)
        • Pituitary Explorer Educational Programme (PEEP)
        • Henning Andersen Educational Programme
        • ESPE Research Fellowship Programme
        • Literature
        • Professional & scientific sites
      • NordiCare® (patient support)
        • Educational resources for patients
        • Patient organisations
      • Our partnership with Save the Children
    • Patient testimonials
      • Patient testimonials
  • +Haemostasis management
    • Product info
      • NovoSeven®
      • Single dose
      • Room temperature stable
    • Haemostasis
      • Management
      • Blood coagulation
    • Disease areas
      • Congenital haemophilia
      • Acquired haemophilia
      • Factor VII deficiency
      • Glanzmann's thrombasthenia
    • Educational
      • Key papers
      • Treatment guidelines
      • Services & links
      • WFH patients' leaflet
      • Patient story
  • +Hormone replacement therapy
    • Our products
      • Introduction
      • Activelle®
      • Novofem®
      • Estrofem®
      • Vagifem®
      • Convenience & compliance
      • Our history in HRT
    • About HRT
      • Introduction
      • Symptoms & complaints
      • Duration of treatment
      • Oestrogen
      • Progestogen
      • Continuous combined HRT
      • Sequential combined HRT
      • Low-dose HRT
    • Learn More
      • WHI Study
      • Million Women Study
      • Osteoporosis restriction
• +Patients
  • +Diabetes care
    • Insulin pens
      • FlexPen®
      • NovoPen® 4
      • NovoPen® 3
      • NovoPen® Junior
      • InnoLet®
      • NovoLet®
      • Innovo®
        • Manual
      • InDuo®
        • Manual
    • Needles
      • NovoFine®
      • NovoFine® Autocover®
      • NovoTwistTM
    • Hypokit
      • Hypokit
    • Diabetes tools
      • Hands On Insulin
      • Living with diabetes
      • For parents
      • For children
      • All about food
      • Communities
      • Hypoglycaemia
      • Insulins
  • +Growth hormone therapy
    • Phamaceutical information
      • What is growth hormone?
    • Injection devices
      • Choosing the right device
      • NordiFlex®
      • NordiFlex PenMate®
      • NordiPen®
      • NordiPenMate®
      • NordiLet®
    • Needles
      • NovoFine®
    • Growth disorders
      • GHD (Growth hormone deficiency)
      • GHDA (Growth hormone deficiency in adults)
      • SGA (Small for gestational age)
      • Turner syndrome
      • Noonan syndrome
      • Skeletal dysplasia
      • Chronic renal insufficiency
    • Programmes & support
      • Interactive tutorial
      • Patient organisations
      • Our partnership with Save the Children
  • +Haemostasis management
    • Haemostasis
      • What is haemostasis?
      • Haemostasis management
    • Disease areas
      • Introduction
      • Congenital haemophilia
      • Acquired haemophilia
      • Factor VII deficiency
      • Glanzmann's thrombasthenia
    • Educational
      • Links
      • Patient story
  • +Hormone replacement therapy
    • About HRT
      • Introduction
      • Duration of treatment
      • Oestrogen
      • Progestogen
      • Continuous combined HRT
      • Sequential combined HRT
      • Low-dose HRT
    • About the menopause
      • Introduction
      • Symptoms & complaints
      • Hormonal interaction
      • Hormonal imbalance
      • Atrophic vaginitis
• +Investors
  • News
  • Novo Nordisk in short
    • Key facts
    • Dividend policy
    • Financial targets
    • Rating strategy
  • Calendar
  • Download centre
  • Conference calls
  • Corporate Governance
  • IR guidelines
  • IR Contacts
  • R&D pipeline
  • Share information
    • Facts about the share
    • Trading in shares
    • Disclosure obligations of major shareholders
    • Dividend and capital history
    • Downloadable financial data
    • Analyst coverage
    • Biograhies of Novo Nordisk Executive Management
  • Sustainability
  • Subscription
  • FAQ
• +Media
  • News
  • Facts about Novo Nordisk
  • R&D pipeline
  • Download centre
  • Diabetes dictionary
  • Broadcast room
  • Photos
  • Subscription
  • Victoza® (liraglutide) press room
    • News archive
    • Backgrounders
    • Animations
    • B-roll
    • Photos
    • Frequently asked questions
    • Relevant links
  • Contact
• +R&D
  • R&D at a glance
  • About R&D
    • Organisation
    • Diabetes Research Unit
    • Biopharmaceuticals Research Unit
    • Device R&D
    • Global Development
    • Chemistry, Manufacturing and Control Supply
    • Regulatory Affairs
  • Pipeline
    • Diabetes
    • Growth Hormone
    • Haemostasis
    • Inflammation
    • Other therapies
  • Partnering
    • Why partner with us?
    • Being partner with us
    • Diabetes
    • Protein Delivery
    • Haemophilia
    • Growth disorders
    • Inflammation
    • Partnerships
    • Protein expertise
    • Clinical research partnerships
    • Novo Nordisk Biotech Fund
    • Contact us
  • Scientific publications
  • Bioethics
    • Bioethics at Novo Nordisk
    • Clinical trial ethics
    • Stem cell ethics
    • Animal ethics
    • Gene technology ethics
  • From idea to patient
  • Fellowships
    • Scandinavian Return Fellowships
    • Co-financed PhD Fellowships
    • Scholarships
  • Novo Nordisk Trials
  • Contact us
• +Jobs
  • Working at Novo Nordisk
    • Testimonials
    • What makes us tick
    • Once you're in
    • Programmes for you
    • Reputation - inside and out
    • Doing it the right way
    • Life changing careers in Denmark
    • Locations
  • Jobs
  • MD and scientist programmes
    • Return Fellowships for Scandinavian Scientists
    • Pharmaceutical Medicine Programme
  • Graduate programmes
    • Graduate frontpage
    • Your opportunities
    • The 10 graduate programmes
    • Read graduate blogs
    • Your career after Base Camp
    • Apply to Base Camp
    • Download area
  • Trainees
    • Derfor Novo Nordisk
    • De 11 uddannelser
    • Hvem er du?
    • Fakta
    • Ansøg
    • Kontakt
    • Download
  • Tips for your application
    • The hiring process
    • The application
    • Use of personality test
    • Unsolicited application
  • Contact or meet us
  • Hagedorn Research Institute
  • Oral Protein Formulation
    • Revolutionising diabetes treatment
    • Why we are passionate
    • Available OPF jobs
  • Test your Novo Nordisk knowledge
  • Jobs in NNIT
  • Jobs in NNE Pharmaplan
• +Sustainability
  • How we manage sustainably
    • The Triple Bottom Line
    • Stakeholder engagement
    • Awards and recognition
  • Our positions
    • Access to health
    • Animal experimentation
    • Climate change
    • Clinical trials
    • Gene technology
    • Human rights
    • Intellectual property rights
    • Non-human primates
    • Stem cells
  • Our priorities
    • Access to health
    • Responsible business practices
    • Our people
    • Environment and climate change
    • Community engagement
  • Our reporting
  • News on progress
  • Try our interactive challenges
  • Get in touch
• +About us
  • Novo Nordisk in brief
    • Ownership
    • Facts and figures
    • History
    • Our logo
  • Novo Nordisk way of management
    • Our vision
    • The charter
    • The policies
    • View PDF file
  • Management
    • Board of Directors
    • Executive Management
  • Corporate governance
    • Governance model
    • Shareholder Rights
    • Novo Nordisk Foundation
    • General meetings and Shareholders meeting
    • Board of Directors
    • Chairmanship and board committees
    • Audit Committee
    • Executive Management
    • Remuneration policy
    • Self-assessment
    • Risk management
    • Internal control
    • Assurance
    • Audit
    • Benchmark 2007
    • Codes and practices
  • Global offices
  • Changing diabetes®
    • About Changing Diabetes®
    • Our Corporate Brand
    • Our Brand Promise
    • Changing Diabetes® in action
    • Changing Diabetes® e-newsletter
  • Changing Possibilities in Haemophilia®
    • Foundation
    • History
  • Download centre
  • Contact us